Caris Life Sciences Announces Published Results Showing that its ADAPT Biotargeting System Effectively Stratified Breast Cancer Patients Based on Their Benefit from Trastuzumab Treatment (Herceptin)

Data featured in Nature Communications showed ADAPT Biotargeting System significantly out-performed industry standard HER2 testing

IRVING, Texas, March 23, 2018 -- (Healthcare Sales & Marketing Network) -- Caris Life Sciences®, a leading innovator ... Biopharmaceuticals, Diagnostics, Oncology Caris Life Sciences, ADAPT Biotargeting System, trastuzumab, Herceptin

Source: HSMN NewsFeed - March 23, 2018 Category: Pharmaceuticals Source Type: news